Ronald H. Goldstein MD
Voluntary Professor, Pulmonary, Allergy, Sleep & Critical Care Medicine
Voluntary Research Assistant Professor, Biochemistry & Cell Biology
72 E. Concord Street | (617) 638-4860jonina@bu.edu
Sections
Pulmonary, Allergy, Sleep & Critical Care Medicine
Centers
Pulmonary Center
Biography
Our laboratory is exploring the regulation of the alveolar matrix during the development of early emphysema and fibrosis. The loss of matrix substances results in emphysema whereas the excessive deposition of matrix substances results in pulmonary fibrosis. Employing the techniques of cellular and molecular biology, we are developing methods to modulating the levels of collagen, elastin and other key matrix substances in the alveolar wall. These approaches are studied in wild type and transgenic murine models of emphysema and fibrosis.
We have extensive experience in the diagnosis and management of individuals with pulmonary fibrosis. In human studies, our clinical experimental interest involves the use of novel substances to treat idiopathic pulmonary fibrosis (IPF). We participate in several clinical studies to evaluate the efficacy of these agents in the pathogenesis of IPF.
Research special interests include: Pulmonary Matrix Biology related to Pulmonary Fibrosis and Emphysema
Clinical special interests include: Pulmonary Fibrosis
Other Positions
Education
MD, SUNY Downstate Medical Center, 1973
BS, University of Wisconsin-Madison, 1969
Publications
Johnson SW, Finlay L, Mathai SC, Goldstein RH, Maron BA. Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing. Pulm Circ. 2022 Jul; 12(3):e12126. PMID: 36092795.
Published on 3/14/2022Maron BA, Choudhary G, Goldstein RL, Garshick E, Jankowich M, Tucker TJS, LaCerda KA, Hattler B, Dempsey EC, Sadikot RT, Shapiro S, Rounds SI, Goldstein RH. Tadalafil for veterans with chronic obstructive pulmonary disease-pulmonary hypertension: A multicenter, placebo-controlled randomized trial. Pulm Circ. 2022 Jan; 12(1):e12043. PMID: 35506072.
Published on 11/1/2020Clark K, Goldstein R, Maron B, Breu AC. A Veteran Presenting With Chronic Progressive Dyspnea on Exertion. Fed Pract. 2020 Nov; 37(11):522-526. PMID: 33328718.
Published on 7/27/2020Maron BA, Brittan EL, Hess E, Waldo SW, Barón AE, Huang S, Goldstein RH, Assad T, Wertheim BM, Alba GA, Leopold JA, Olschewski H, Galiè N, Simonneau G, Kovacs G, Tedford RJ, Humbert M, Choudhary G. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med. 2020 09; 8(9):873-884. PMID: 32730752.
Published on 2/12/2016Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, Joynt KE, Kass DJ, Stephens T, Stanislawski MA, Swenson ER, Goldstein RH, Leopold JA, Zamanian RT, Elwing JM, Plomondon ME, Grunwald GK, Barón AE, Rumsfeld JS, Choudhary G. Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation. 2016 Mar 29; 133(13):1240-8. PMID: 26873944.
Published on 12/1/2015Berry NC, Manyoo A, Oldham WM, Stephens TE, Goldstein RH, Waxman AB, Tracy JA, Leary PJ, Leopold JA, Kinlay S, Opotowsky AR, Systrom DM, Maron BA. Protocol for exercise hemodynamic assessment: performing an invasive cardiopulmonary exercise test in clinical practice. Pulm Circ. 2015 Dec; 5(4):610-8. PMID: 26697168.
Published on 12/1/2013Maron BA, Goldstein RH, Rounds SI, Shapiro S, Jankowich M, Garshick E, Moy ML, Gagnon D, Choudhary G. Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial. Pulm Circ. 2013 Dec; 3(4):889-97. PMID: 25006405.
Published on 5/10/2012Golan-Gerstl R, Wallach-Dayan SB, Zisman P, Cardoso WV, Goldstein RH, Breuer R. Cellular FLICE-like inhibitory protein deviates myofibroblast fas-induced apoptosis toward proliferation during lung fibrosis. Am J Respir Cell Mol Biol. 2012 Sep; 47(3):271-9. PMID: 22582174.
Published on 5/1/2012Yu J, Taylor L, Rich C, Toselli P, Stone P, Green D, Warburton R, Hill N, Goldstein R, Polgar P. Transgenic expression of an altered angiotensin type I AT1 receptor resulting in marked modulation of vascular type I collagen. J Cell Physiol. 2012 May; 227(5):2013-21. PMID: 21751211.
Published on 6/12/2010Brooks WW, Shen S, Conrad CH, Goldstein RH, Deng LL, Bing OH. Transcriptional changes associated with recovery from heart failure in the SHR. J Mol Cell Cardiol. 2010 Sep; 49(3):390-401. PMID: 20547165.